drugset / Trial / NCT00102947

Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections

NCT00102947

Phase 4 Terminated 72 enrolled Merck & Co., Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous (i.v.) daptomycin and the safety and efficacy of daptomycin relative to comparator in the treatment of complicated skin and skin structure infections in patients with renal impairment.

Timeline

Start
2005-01
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified Intravenous

Indications

No indication recorded.